119 results on '"Sargent, Michelle A."'
Search Results
102. Cardiac Myosin Binding Protein-C Phosphorylation in a β-Myosin Heavy Chain Background
- Author
-
Sadayappan, Sakthivel, primary, Gulick, James, additional, Klevitsky, Raisa, additional, Lorenz, John N., additional, Sargent, Michelle, additional, Molkentin, Jeffery D., additional, and Robbins, Jeffrey, additional
- Published
- 2009
- Full Text
- View/download PDF
103. Genetic Manipulation of Periostin Expression in the Heart Does Not Affect Myocyte Content, Cell Cycle Activity, or Cardiac Repair
- Author
-
Lorts, Angela, primary, Schwanekamp, Jennifer A., additional, Elrod, John W., additional, Sargent, Michelle A., additional, and Molkentin, Jeffery D., additional
- Published
- 2009
- Full Text
- View/download PDF
104. Abstract 1432: Cardiomyocyte Myostatin Contributes to Skeletal Muscle Wasting in Heart Failure
- Author
-
Heineke, Joerg, primary, Auger-Messier, Mannix, additional, Sargent, Michelle, additional, York, Allen, additional, Welle, Stephen, additional, and Molkentin, Jeffery D, additional
- Published
- 2008
- Full Text
- View/download PDF
105. Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart
- Author
-
Heineke, Joerg, primary, Auger-Messier, Mannix, additional, Xu, Jian, additional, Oka, Toru, additional, Sargent, Michelle A., additional, York, Allen, additional, Klevitsky, Raisa, additional, Vaikunth, Sachin, additional, Duncan, Stephen A., additional, Aronow, Bruce J., additional, Robbins, Jeffrey, additional, Crombleholme, Timothy M., additional, and Molkentin, Jeffery D., additional
- Published
- 2008
- Full Text
- View/download PDF
106. Genetic Manipulation of Periostin Expression Reveals a Role in Cardiac Hypertrophy and Ventricular Remodeling
- Author
-
Oka, Toru, primary, Xu, Jian, additional, Kaiser, Robert A., additional, Melendez, Jaime, additional, Hambleton, Michael, additional, Sargent, Michelle A., additional, Lorts, Angela, additional, Brunskill, Eric W., additional, Dorn, Gerald W., additional, Conway, Simon J., additional, Aronow, Bruce J., additional, Robbins, Jeffrey, additional, and Molkentin, Jeffery D., additional
- Published
- 2007
- Full Text
- View/download PDF
107. Dissection of Thrombospondin-4 Domains Involved in Intracellular Adaptive Endoplasmic Reticulum Stress-Responsive Signaling.
- Author
-
Brody, Matthew J., Schips, Tobias G., Vanhoutte, Davy, Kanisicak, Onur, Karch, Jason, Maliken, Bryan D., Blair, N. Scott, Sargent, Michelle A., Prasad, Vikram, and Molkentin, Jeffery D.
- Subjects
THROMBOSPONDINS ,GLYCOPROTEINS ,ENDOPLASMIC reticulum ,HEART cells ,EXTRACELLULAR matrix proteins - Abstract
Thrombospondins are a family of stress-inducible secreted glycoproteins that underlie tissue remodeling. We recently reported that thrombospondin-4 (Thbs4) has a critical intracellular function, regulating the adaptive endoplasmic reticulum (ER) stress pathway through activating transcription factor 6a (Atf6α). In the present study, we dissected the domains of Thbs4 that mediate interactions with ER proteins, such as BiP (Grp78) and Atf6α, and the domains mediating activation of the ER stress response. Functionally, Thbs4 localized to the ER and post-ER vesicles and was actively secreted from cardiomyocytes, as were the type III repeat (T3R) and TSP-C domains, while the LamG domain localized to the Golgi apparatus. We also mutated the major calcium-binding motifs within the T3R domain of full-length Thbs4, causing ER retention and secretion blockade. The T3R and TSP-C domains as well as wild-type Thbs4 and the calcium-binding mutant interacted with Atf6α, induced an adaptive ER stress response, and caused expansion of intracellular vesicles. In contrast, overexpression of a related secreted oligomeric glycoprotein, Nell2, which lacks only the T3R and TSP-C domains, did not cause these effects. Finally, deletion of Atf6α abrogated Thbs4- induced vesicular expansion. Taken together, these data identify the critical intracellular functional domains of Thbs4, which was formerly thought to have only extracellular functions. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
108. Na+ Dysregulation Coupled with Ca2+ Entry through NCX1 Promotes Muscular Dystrophy in Mice.
- Author
-
Burr, Adam R., Millay, Douglas P., Goonasekera, Sanjeewa A., Ki Ho Park, Sargent, Michelle A., Collins, James, Altamirano, Francisco, Philipson, Kenneth D., Allen, Paul D., Jianjie Ma, López, José Rafael, and Molkentin, Jeffery D.
- Subjects
SODIUM-calcium exchanger ,MUSCULAR dystrophy ,SKELETAL muscle ,TRANSGENIC mice ,LABORATORY mice - Abstract
Unregulated Ca
2+ entry is thought to underlie muscular dystrophy. Here, we generated skeletal-muscle-specific transgenic (TG) mice expressing the Na+ -Ca2+ exchanger 1 (NCX1) to model its identified augmentation during muscular dystrophy. The NCX1 transgene induced dystrophy-like disease in all hind-limb musculature, as well as exacerbated the muscle disease phenotypes in δ-sarcoglycan (Sgcd-/- ), Dysf-/- , and mdx mouse models of muscular dystrophy. Antithetically, muscle-specific deletion of the Slc8a1 (NCX1) gene diminished hind-limb pathology in Sgcd-/- mice. Measured increases in baseline Na+ and Ca2+ in dystrophic muscle fibers of the hind-limb musculature predicts a net Ca2+ influx state due to reverse-mode operation of NCX1, which mediates disease. However, the opposite effect is observed in the diaphragm, where NCX1 overexpression mildly protects from dystrophic disease through a predicted enhancement in forward-mode NCX1 operation that reduces Ca2+ levels. Indeed, Atpla2+/- (encoding Na+ -K+ ATPase α2) mice, which have reduced Na+ clearance rates that would favor NCX1 reverse-mode operation, showed exacerbated disease in the hind limbs of NCX1 TG mice, similar to treatment with the Na+ -K+ ATPase inhibitor digoxin. Treatment of Sgcd-/- mice with ranolazine, a broadly acting Na+ channel inhibitor that should increase NCX1 forward-mode operation, reduced muscular pathology. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
109. ASK1 Regulates Cardiomyocyte Death but Not Hypertrophy in Transgenic Mice.
- Author
-
Qinghang Liu, Sargent, Michelle A., York, Allen J., and Molkentin, Jeffery D.
- Subjects
PROTEIN kinases ,APOPTOSIS ,CARDIAC hypertrophy ,TRANSGENIC mice ,CARDIOMYOPATHIES - Abstract
The article presents a study regarding the role of apoptosis signal-regulating kinase (ASK)1 in cardiac hypertrophic response regulation in vivo. The researchers generated transgenic mice with overexpression of ASK1 in the heart to analyze its gain-of-function effect. It cites its findings and conclusion that ASK1 does not directly regulate cardiac hypertrophic response but does change cell death and tendency to cardiomyopathy through a mechanism dependent to calcineurin.
- Published
- 2009
- Full Text
- View/download PDF
110. Cardiac myosin binding protein-C phosphorylation in a {beta}-myosin heavy chain background.
- Author
-
Sadayappan S, Gulick J, Klevitsky R, Lorenz JN, Sargent M, Molkentin JD, Robbins J, Sadayappan, Sakthivel, Gulick, James, Klevitsky, Raisa, Lorenz, John N, Sargent, Michelle, Molkentin, Jeffery D, and Robbins, Jeffrey
- Published
- 2009
- Full Text
- View/download PDF
111. Stéréochimie de la réduction des α-iminocétones. Étude de l'effet des substituants par une approche quantitative des facteurs gouvernant la stéréosélectivité.
- Author
-
Alcaide, Benito, Mardomingo, Carmen L., Pérez-Ossorio, Rafael, Plumet, Joaquin, Phan-Tan-Luu, Roger, and Sargent, Michelle
- Published
- 1985
- Full Text
- View/download PDF
112. Genetic Lineage Tracing of Sca-1+ Cells Reveals Endothelial but Not Myogenic Contribution to the Murine Heart.
- Author
-
Vagnozzi, Ronald J, Sargent, Michelle A, Lin, Suh-Chin J, Palpant, Nathan J, Murry, Charles E, and Molkentin, Jeffery D
- Abstract
Background: The adult mammalian heart displays a cardiomyocyte turnover rate of ≈1%/y throughout postnatal life and after injuries such as myocardial infarction (MI), but the question of which cell types drive this low level of new cardiomyocyte formation remains contentious. Cardiac-resident stem cells marked by stem cell antigen-1 (Sca-1, gene name Ly6a) have been proposed as an important source of cardiomyocyte renewal. However, the in vivo contribution of endogenous Sca-1+ cells to the heart at baseline or after MI has not been investigated.Methods: Here we generated Ly6a gene-targeted mice containing either a constitutive or an inducible Cre recombinase to perform genetic lineage tracing of Sca-1+ cells in vivo.Results: We observed that the contribution of endogenous Sca-1+ cells to the cardiomyocyte population in the heart was <0.005% throughout all of cardiac development, with aging, or after MI. In contrast, Sca-1+ cells abundantly contributed to the cardiac vasculature in mice during physiological growth and in the post-MI heart during cardiac remodeling. Specifically, Sca-1 lineage-traced endothelial cells expanded postnatally in the mouse heart after birth and into adulthood. Moreover, pulse labeling of Sca-1+ cells with an inducible Ly6a-MerCreMer allele also revealed a preferential expansion of Sca-1 lineage-traced endothelial cells after MI injury in the mouse.Conclusions: Cardiac-resident Sca-1+ cells are not significant contributors to cardiomyocyte renewal in vivo. However, cardiac Sca-1+ cells represent a subset of vascular endothelial cells that expand postnatally with enhanced responsiveness to pathological stress in vivo. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
113. Abstract 15850: An Acute Immune Response Underlies the Benefit of Cardiac Adult Stem Cell Therapy
- Author
-
Vagnozzi, Ronald J, Maillet, Marjorie, Sargent, Michelle A, Khalil, Hadi, Johansen, Anne Katrine, Schwanekamp, Jennifer, York, Allen, Huang, Vincent, Nahrendorf, Matthias, Sadayappan, Sakthivel, and Molkentin, Jeff D
- Abstract
Introduction:Attempts to regenerate or repair the injured heart have employed adult stem or progenitor-like cell types, mostly mononuclear bone marrow cells (BM-MNCs) or mesenchymal stromal cells (MSCs) from multiple sources including the heart itself. However, efficacy of cardiac cell therapy remains highly contested and the therapeutic mechanisms are undefined.Hypothesis:Although release of regenerative paracrine factors from implanted cells has been implicated, poor cell retention (hours to a few days) suggests that active paracrine signaling would be limited. Thus, we set out to determine the primary mechanism responsible for any sustained improvement in cardiac function seen with adult stem cell therapy.Methods and Results:Here we used a murine model of intracardiac BM-MNC or cardiac-derived MSC injection. Injected cells were rapidly cleared and evoked an acute biphasic macrophage response, with an initial infiltration of CCR2+inflammatory monocytes and macrophages followed by immunomodulatory and pro-healing CX3CR1+macrophages. Cell therapy significantly improved cardiac function after myocardial infarction (MI), while both immunosuppression and genetic loss of CX3CR1 ablated this functional benefit. Strikingly, delivery of non-viable cell lysates or zymosan, a non-cellular inflammatory agent, also induced macrophage recruitment and functional benefit post-MI. Mechanistically, the macrophage response from either cell therapy or zymosan injection resulted in favorable extracellular matrix remodeling, which improved regional infarct tissue mechanics and attenuated pro-fibrotic gene expression.Conclusions:Induction of acute inflammation without paracrine factors was sufficient to recapitulate the benefits of cell therapy in a murine model of MI. Our data suggest injection of any cell type which induces an acute inflammatory response and activity of tissue remodeling CX3CR1+macrophages may provide benefit, explaining past similar results across various cell types. Modulating the cardiac macrophage response without the need for cell delivery may represent an alternate approach to stimulate repair and improve function of the infarcted heart.
- Published
- 2019
- Full Text
- View/download PDF
114. Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart.
- Author
-
Xing Fu, Khalil, Hadi, Kanisicak, Onur, Boyer, Justin G., Vagnozzi, Ronald J., Maliken, Bryan D., Sargent, Michelle A., Prasad, Vikram, Valiente-Alandi, Iñigo, Blaxall, Burns C., Molkentin, Jeffery D., and Fu, Xing
- Subjects
- *
FIBROBLASTS , *LABORATORY mice , *CELLS , *GENE expression , *LABORATORY animals - Abstract
Fibroblasts are a dynamic cell type that achieve selective differentiated states to mediate acute wound healing and long-term tissue remodeling with scarring. With myocardial infarction injury, cardiomyocytes are replaced by secreted extracellular matrix proteins produced by proliferating and differentiating fibroblasts. Here, we employed 3 different mouse lineage-tracing models and stage-specific gene profiling to phenotypically analyze and classify resident cardiac fibroblast dynamics during myocardial infarction injury and stable scar formation. Fibroblasts were activated and highly proliferative, reaching a maximum rate within 2 to 4 days after infarction injury, at which point they expanded 3.5-fold and were maintained long term. By 3 to 7 days, these cells differentiated into myofibroblasts that secreted abundant extracellular matrix proteins and expressed smooth muscle α-actin to structurally support the necrotic area. By 7 to 10 days, myofibroblasts lost proliferative ability and smooth muscle α-actin expression as the collagen-containing extracellular matrix and scar fully matured. However, these same lineage-traced initial fibroblasts persisted within the scar, achieving a new molecular and stable differentiated state referred to as a matrifibrocyte, which was also observed in the scars of human hearts. These cells express common and unique extracellular matrix and tendon genes that are more specialized to support the mature scar. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
115. Decreased cardiac L-type Ca2+ channel activity induces hypertrophy and heart failure in mice.
- Author
-
Goonasekera, Sanjeewa A., Hammer, Karin, Auger-Messier, Mannix, Bodi, Ilona, Xiongwen Chen, Hongyu Zhang, Reiken, Steven, Elrod, John W., Correll, Robert N., York, Allen J., Sargent, Michelle A., Hofmann, Franz, Moosmang, Sven, Marks, Andrew R., Houser, Steven R., Bers, Donald M., and Molkentin, Jeffery D.
- Subjects
- *
CALCIUM channels , *ION channels , *CARDIOVASCULAR diseases , *HEART diseases , *HEART cells - Abstract
Antagonists of L-type Ca2+ channels (LTCCs) have been used to treat human cardiovascular diseases for decades. However, these inhibitors can have untoward effects in patients with heart failure, and their overall therapeutic profile remains nebulous given differential effects in the vasculature when compared with those in cardiomyocytes. To investigate this issue, we examined mice heterozygous for the gene encoding the pore-forming subunit of LTCC (calcium channel, voltage-dependent, L type, α1C subunit [Cacna1c mice; referred to herein as α1C-/+ mice]) and mice in which this gene was loxP targeted to achieve graded heart-specific gene deletion (termed herein α1C-loxP mice). Adult cardiomyocytes from the hearts of α1C-/+ mice at 10 weeks of age showed a decrease in LTCC current and a modest decrease in cardiac function, which we initially hypothesized would be cardioprotective. However, α1C-/+ mice subjected to pressure overload stimulation, isoproterenol infusion, and swimming showed greater cardiac hypertrophy, greater reductions in ventricular performance, and greater ventricular dilation than α1C+/+ controls. The same detrimental effects were observed in α1C-loxP animals with a cardiomyocytespecific deletion of one allele. More severe reductions in α1C protein levels with combinatorial deleted alleles produced spontaneous cardiac hypertrophy before 3 months of age, with early adulthood lethality. Mechanistically, our data suggest that a reduction in LTCC current leads to neuroendocrine stress, with sensitized and leaky sarcoplasmic reticulum Ca2+ release as a compensatory mechanism to preserve contractility. This state results in calcineurin/nuclear factor of activated T cells signaling that promotes hypertrophy and disease. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
116. Plasma membrane Ca2+-ATPase isoform 4 antagonizes cardiac hypertrophy in association with calcineurin inhibition in rodents.
- Author
-
Xu Wu, Baojun Chang, Blair, N. Scott, Sargent, Michelle, York, Allen J., Robbins, Jeffrey, Shull, Gary E., Molkentin, Jeffery D., Wu, Xu, and Chang, Baojun
- Subjects
- *
CELL membranes , *HEART cells , *HYPERTROPHY , *COUPLING constants , *TRANSGENIC mice , *FIBROSIS , *GENETIC regulation , *CELL metabolism , *PROTEIN metabolism , *ANIMAL experimentation , *CARRIER proteins , *CELL culture , *CELLS , *CELLULAR signal transduction , *COMPARATIVE studies , *CARDIAC hypertrophy , *IMMUNOSUPPRESSIVE agents , *RESEARCH methodology , *MEDICAL cooperation , *MICE , *RECOMBINANT proteins , *RESEARCH , *RESEARCH funding , *EVALUATION research , *PREVENTION - Abstract
How Ca2+-dependent signaling effectors are regulated in cardiomyocytes, given the extreme cytoplasmic Ca2+ concentration changes that underlie contraction, remains unknown. Cardiomyocyte plasma membrane Ca2+-ATPase (PMCA) extrudes Ca2+ but has little effect on excitation-contraction coupling, suggesting its potential role in controlling Ca2+-dependent signaling effectors such as calcineurin. We generated cardiac-specific inducible PMCA4b transgenic mice that displayed normal global Ca2+ transient and cellular contraction levels and reduced cardiac hypertrophy following transverse aortic constriction (TAC) or phenylephrine/Ang II infusion, but showed no reduction in exercise-induced hypertrophy. Transgenic mice were protected from decompensation and fibrosis following long-term TAC. The PMCA4b transgene reduced the hypertrophic augmentation associated with transient receptor potential canonical 3 channel overexpression, but not that associated with activated calcineurin. Furthermore, Pmca4 gene-targeted mice showed increased cardiac hypertrophy and heart failure events after TAC. Physical associations between PMCA4b and calcineurin were enhanced by TAC and by agonist stimulation of cultured neonatal cardiomyocytes. PMCA4b reduced calcineurin nuclear factor of activated T cell-luciferase activity after TAC and in cultured neonatal cardiomyocytes after agonist stimulation. PMCA4b overexpression inhibited cultured cardiomyocyte hypertrophy following agonist stimulation, but much less so in a Ca2+ pumping-deficient PMCA4b mutant. Thus, Pmca4b likely reduces the local Ca2+ signals involved in reactive cardiomyocyte hypertrophy via calcineurin regulation. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
117. Cardiomyocyte GATA4 functions as a stressresponsive regulator of angiogenesis in the murine heart.
- Author
-
Heineke, Joerg, Auger-Messier, Mannix, Jian Xu, Oka, Toru, Sargent, Michelle A., York, Allen, Klevitsky, Raisa, Vaikunth, Sachin, Duncan, Stephen A., Aronow, Bruce J., Robbins, Jeffrey, Cromblehol, Timothy M., and Molkentin, Jeffery D.
- Subjects
- *
TRANSCRIPTION factors , *HEART cells , *NEOVASCULARIZATION , *ENDEMIC flea-borne typhus , *CARDIAC hypertrophy - Abstract
The transcription factor GATA4 is a critical regulator of cardiac gene expression, modulating cardiomyocyte differentiation and adaptive responses of the adult heart. We report what we believe to be a novel function for GATA4 in murine cardiomyocytes as a nodal regulator of cardiac angiogenesis. Conditional overexpression of GATA4 within adult cardiomyocytes increased myocardial capillary and small conducting vessel densities and increased coronary flow reserve and perfusion-dependent cardiac contractility. Coculture of HUVECs with either GATA4-expressing cardiomyocytes or with myocytes expressing a dominant-negative form of GATA4 enhanced or reduced HUVEC tube formation, respectively. Expression of GATA4 in skeletal muscle by adenoviral gene transfer enhanced capillary densities and hindlimb perfusion following femoral artery ablation. Deletion of Gata4 specifically from cardiomyocytes reduced myocardial capillary density and prevented pressure overload-augmented angiogenesis in vivo. GATA4 induced the angiogenic factor VEGF-A, directly binding the Vegf-A promoter and enhancing transcription. GATA4-overexpressing mice showed increased levels of cardiac VEGF-A, while Gata4-deleted mice demonstrated decreased VEGF-A levels. The induction of HUVEC tube formation in GATA4-overexpressing cocultured myocytes was blocked with a VEGF receptor antagonist. Pressure overload-induced dysfunction in Gata4-deleted hearts was partially rescued by adenoviral gene delivery of VEGF and angiopoietin-1. To our knowledge, these results demonstrate what is to our knowledge a previously unrecognized function for GATA4 as a regulator of cardiac angiogenesis through a nonhypoxic, load, and/or disease-responsive mechanism. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
118. BHLH Transcription Factor TCF21 Inhibits Myofibroblast Formation and Cardiac Fibrosis.
- Author
-
Johansen AKZ, Kasam RK, Vagnozzi RJ, Lin SJ, Gomez-Arroyo JG, Shittu A, Bowers SLK, Kuwabara Y, Grimes KM, Warrick K, Sargent MA, Baldwin TA, Quaggin SE, Barski A, and Molkentin JD
- Abstract
Background: TCF21 (transcription factor 21) is a bHLH (basic helix-loop-helix) protein required for the developmental specification of cardiac fibroblasts (CFs) from epicardial progenitor cells that surround the embryonic heart. In the adult heart, TCF21 is expressed in tissue-resident fibroblasts and is downregulated in response to injury or stimuli leading to myofibroblast differentiation. These findings led to the hypothesis that TCF21 regulates fibroblast differentiation in the adult mammalian heart to affect fibrosis., Methods: Tamoxifen-inducible Cre genetic mouse models were used to permit either Tcf21 gene deletion or its enforced expression in adult CFs. Histological and echocardiographic analyses were used, as well as transcriptomic analysis to determine the consequences of TCF21 gain-of-function and loss-of-function in vivo. Genomic Tcf21 occupancy was identified by chromatin immunoprecipitation and sequencing in CFs. Myocardial infarction and Ang II (angiotensin II)/phenylephrine served as models of cardiac fibrosis., Results: Acute and long-term deletion of Tcf21 in CFs of the adult mouse heart does not alter fibroblast numbers, myofibroblast differentiation, or fibrosis. Fibroblast-specific Tcf21 gene-deleted mice demonstrate no significant alterations in cardiac function or scar formation in response to cardiac injury compared with control mice. In contrast, enforced expression of TCF21 in CFs inhibits myofibroblast differentiation and significantly reduces cardiac fibrosis and hypertrophy in response to 1 week of Ang II/phenylephrine infusion. Mechanistically, sustained TCF21 expression prevents the induction of genes associated with fibrosis and ECM (extracellular matrix) organization., Conclusions: TCF21 expression is not required to maintain the cell state of CFs in the adult heart. However, preventing the normal downregulation of TCF21 expression with injury reduces myofibroblast formation, cardiac fibrosis, and the acute cardiac hypertrophic response following 1 week of Ang II/phenylephrine stimulation.
- Published
- 2024
- Full Text
- View/download PDF
119. Na+ dysregulation coupled with Ca2+ entry through NCX1 promotes muscular dystrophy in mice.
- Author
-
Burr AR, Millay DP, Goonasekera SA, Park KH, Sargent MA, Collins J, Altamirano F, Philipson KD, Allen PD, Ma J, López JR, and Molkentin JD
- Subjects
- Acetanilides pharmacology, Animals, Digoxin pharmacology, Dysferlin, Enzyme Inhibitors pharmacology, Hindlimb pathology, Membrane Proteins genetics, Mice, Mice, Inbred C57BL, Mice, Inbred mdx, Mice, Knockout, Muscle, Skeletal pathology, Piperazines pharmacology, Ranolazine, Sarcoglycans genetics, Sodium Channel Blockers pharmacology, Sodium-Calcium Exchanger genetics, Sodium-Potassium-Exchanging ATPase antagonists & inhibitors, Sodium-Potassium-Exchanging ATPase genetics, Calcium metabolism, Muscular Dystrophy, Animal genetics, Sodium metabolism, Sodium-Calcium Exchanger metabolism
- Abstract
Unregulated Ca(2+) entry is thought to underlie muscular dystrophy. Here, we generated skeletal-muscle-specific transgenic (TG) mice expressing the Na(+)-Ca(2+) exchanger 1 (NCX1) to model its identified augmentation during muscular dystrophy. The NCX1 transgene induced dystrophy-like disease in all hind-limb musculature, as well as exacerbated the muscle disease phenotypes in δ-sarcoglycan (Sgcd(-/-)), Dysf(-/-), and mdx mouse models of muscular dystrophy. Antithetically, muscle-specific deletion of the Slc8a1 (NCX1) gene diminished hind-limb pathology in Sgcd(-/-) mice. Measured increases in baseline Na(+) and Ca(2+) in dystrophic muscle fibers of the hind-limb musculature predicts a net Ca(2+) influx state due to reverse-mode operation of NCX1, which mediates disease. However, the opposite effect is observed in the diaphragm, where NCX1 overexpression mildly protects from dystrophic disease through a predicted enhancement in forward-mode NCX1 operation that reduces Ca(2+) levels. Indeed, Atp1a2(+/-) (encoding Na(+)-K(+) ATPase α2) mice, which have reduced Na(+) clearance rates that would favor NCX1 reverse-mode operation, showed exacerbated disease in the hind limbs of NCX1 TG mice, similar to treatment with the Na(+)-K(+) ATPase inhibitor digoxin. Treatment of Sgcd(-/-) mice with ranolazine, a broadly acting Na(+) channel inhibitor that should increase NCX1 forward-mode operation, reduced muscular pathology.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.